ImmunityBio, Inc. (IBRX)

About ImmunityBio, Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

As of November 3, 2026, ImmunityBio, Inc. (IBRX) stock climbed to $8.27, up 4.03% (+$0.32) versus the previous close. On the day, shares have traded between $7.97 and $8.43. That puts IBRX around the middle of its 52-week range of $1.95 to $12.43. ImmunityBio, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $8.79 billion, with about 2.37 million shares changing hands.

Latest IBRX news

• IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heiststocktwits.com· Nov 2, 11:44 PM ET
• SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focusstocktwits.com· Nov 2, 1:11 AM ET
• SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3stocktwits.com· Oct 30, 1:07 AM ET
• Insmed (INSM) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance· Oct 29, 7:35 AM ETINSM
• Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Yahoo Finance· Oct 29, 2:41 AM ETPRME
• IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wavestocktwits.com· Oct 27, 3:14 AM ET
• Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?Yahoo Finance· Oct 22, 8:40 AM ETHSCS
• ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nearsstocktwits.com· Oct 21, 9:35 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want IBRX headlines, alerts and AI research in one place? Create a free account →

• $IBRX primed for continuation

  @topstockalerts· Nov 3, 11:15 AM ET

• $IBRX Primary goal met: No dose-limiting toxicities (DLTs) at any dose, including the highest tested (\(5 \times 10^{11}\) virus particles). MTD was not reached, and no patients stopped treatment because of side effects. Safety looks clean: Mostly Grade 1–2 injection-site reac…

  @Whatever2020· Nov 3, 11:11 AM ET

• $IBRX lol 10-6-26 blow by 11

  @Speedbaron· Nov 3, 11:07 AM ET

• $IBRX PSS will have some really juicy guidance next week.

  @PeelonDusk· Nov 3, 11:01 AM ET

• $IBRX Friends and fellow investors, the Bloomberg terminal indicates that the earnings report is gonna be delivered in nine days or on Wednesday the 11th. Very bullish! See the picture attached.:

  @Eureka2005· Nov 3, 11:00 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →